Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma Announces Closing of $25 Million Underwritten Offering
TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
View HTML
Toggle Summary RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-104 for Crohn’s Disease and RHB-204 for NTM Infections
Once granted, the new patent, which covers both RHB-104 and RHB-204, is expected to be valid until at least 2029   RedHill recently announced positive top-line results from the randomized, double-blind, placebo-controlled MAP US Phase III study with orally-administered RHB-104 in Crohn’s disease   ...
View HTML
Toggle Summary RedHill Biopharma Announces Pricing of $25 Million Underwritten Offering
TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
View HTML
Toggle Summary RedHill Biopharma Elaborates on Its Announced Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease
TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal (GI) diseases, today ...
View HTML
Toggle Summary RedHill Biopharma Announces Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease
Primary endpoint successfully achieved - superior remission rate at week 26 in patients treated with RHB-104 (p= 0.013)   Key secondary endpoints also met, demonstrating consistent benefit to Crohn’s disease patients treated with RHB-104   RedHill to host conference call and live webcast today, ...
View HTML
Toggle Summary RedHill Biopharma Initiates Co-Promotion of HIV/AIDS Anti-Diarrheal Drug Mytesi®
Mytesi ® is an FDA -approved anti-diarrheal prescription drug indicated for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on anti-retroviral therapy (ART) Mytesi ® is the fourth product being promoted by RedHill's gastrointestinal-focused U.S. ...
View HTML
Toggle Summary RedHill Biopharma Enrolls 400th Patient in Confirmatory Phase III Study with TALICIA® for H. pylori Infection
400 of the planned total of 444 patients have been enrolled in the ongoing confirmatory U.S. Phase III study with TALICIA ® for  H. pylori infection (ERADICATE Hp2) RedHill expects to complete enrollment in the Phase III ERADICATE Hp2 study in coming weeks and announce top-line results in Q4/2018 ...
View HTML
Toggle Summary RedHill Biopharma Announces Uplisting to Nasdaq Global Market
TEL-AVIV, Israel and RALEIGH, N.C. , July 23, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
View HTML
Toggle Summary RedHill Biopharma Announces Allowance of Two New RHB-104 Patents Ahead of Top-Line Phase III Results for Crohn’s Disease
RedHill has received Notices of Allowance for two new patents covering RHB-104 in the U.S. and Europe which are expected to be valid until at least 2029, once granted   Top-line results from the first Phase III study with RHB-104 for Crohn’s disease are expected to be announced in the coming weeks  ...
View HTML
Toggle Summary RedHill Biopharma Announces U.S. Co-Promotion Agreement with Napo Pharmaceuticals for HIV/AIDS Anti-Diarrheal Drug Mytesi®
RedHill has been granted the exclusive right to co-promote Mytesi ® (crofelemer 125 mg delayed-release tablets) in the U.S. to certain gastroenterologists and primary care physicians for the approved indication in people living with HIV/AIDS by Napo Pharmaceuticals , a subsidiary of Jaguar Health ...
View HTML